War Chest Bolstered: Therini Bio Accelerates Attack on Neurodegeneration

Therini Bio secures an additional $39M, supercharging its Series A to a formidable $75M.
This crucial funding propels lead candidate THN391 into Phase 1b trials for Alzheimer’s Disease and Diabetic Macular Edema.
Therini’s pioneering strategy targets fibrin-driven neuroinflammation, a novel approach to combat devastating neurodegenerative diseases^{1, 2}.

In a high-stakes battle against the relentless progression of neurodegenerative diseases, Therini Bio has just received a massive infusion of resources. The company announced a $39 million extension to its Series A financing, catapulting the total to an impressive $75 million^{2, 4}. This war chest, fortified by new heavyweight investors Angelini Ventures and Apollo Health Ventures, is set to fuel a critical new phase in the company’s quest to conquer conditions like Alzheimer’s Disease (AD) and Diabetic Macular Edema (DME)^{4, 5, 8}.

Therini Bio is not just fighting symptoms; it’s targeting the insidious root causes. Their groundbreaking approach focuses on vascular dysfunction and the toxic accumulation of fibrin deposits that trigger chronic neuroinflammation and lay waste to neural pathways^{1, 2}. At the vanguard of this assault is THN391, a first-in-class antibody engineered to selectively neutralize fibrin’s inflammatory assault without disrupting essential clotting^{1, 7}. Early trials have shown THN391 to be well-tolerated, a beacon of hope for a new therapeutic dawn⁷.

“Their support enables us to significantly advance our shared vision,” declared Tara Nickerson, Ph.D., CEO of Therini Bio, underscoring the collaborative power driving this mission. With these new funds, Therini Bio is now poised to advance THN391 into Phase 1b trials, bringing this innovative therapy directly to patients and potentially rewriting the future for millions². Thomas Thestrup of Angelini Ventures lauded Therini's "truly novel approach" and "groundbreaking path," reinforcing the excitement surrounding this potential paradigm shift in treating these debilitating diseases⁴.

War Chest Bolstered: Therini Bio Accelerates Attack on Neurodegeneration

References

Stay Updated!